Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy
Số trang: 15
Loại file: pdf
Dung lượng: 2.06 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
The modified systemic inflammation score (mSIS) system, which is constructed based on the neutrophil to lymphocyte ratio (NLR) and albumin (Alb), has not been applied to evaluate the prognosis of malignant breast cancer patients who underwent neoadjuvant chemotherapy (NAC). The present study aimed to explore the relationship between the mSIS and overall survival (OS), disease-free survival (DFS) and pathological complete response (pCR).
Nội dung trích xuất từ tài liệu:
Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy
Nội dung trích xuất từ tài liệu:
Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Breast cancer Modified systemic inflammation score Neutrophil to lymphocyte ratio Malignant breast cancer patients Pathological complete responseGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 167 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 108 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 35 0 0
-
12 trang 33 0 0